The HSP90 inhibitor 17-N-allylamino-17-demethoxy geldanamycin (17-AAG) synergizes with cisplatin and induces apoptosis in cisplatin-resistant esophageal squamous cell carcinoma cell lines via the Akt/XIAP pathway

  • Authors:
    • Takashi Ui
    • Kazue Morishima
    • Shin Saito
    • Yuji Sakuma
    • Hirofumi Fujii
    • Yoshinori Hosoya
    • Shumpei Ishikawa
    • Hiroyuki Aburatani
    • Masashi Fukayama
    • Toshiro Niki
    • Yoshikazu Yasuda
  • View Affiliations

  • Published online on: December 5, 2013     https://doi.org/10.3892/or.2013.2899
  • Pages: 619-624
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Although cisplatin (CDDP) is a key drug in the treatment of esophageal squamous cell carcinoma (ESCC), acquired chemoresistance remains a major problem. Combination therapy may represent one strategy to overcome this resistance. Heat shock protein 90 (HSP90) is known to be overexpressed in several types of cancer cells, and its inhibition by small molecules, either alone or in combination, has shown promise in the treatment of solid malignancies. In the present study, we evaluated the synergistic effects of combining CDDP with the HSP90 inhibitor 17-N-allylamino-17-demethoxy geldanamycin (17-AAG) on two CDDP-resistant human esophageal squamous cancer cell lines, KYSE30 and KYSE150. The results obtained demonstrated the synergistic inhibitory effects of CDDP and 17-AAG on the growth of KYSE30 and KYSE150 cells. Cell growth and cell number were more effectively reduced by the combined treatment with CDDP and 17-AAG than by the treatment with either CDDP or 17-AAG alone. Western blotting revealed that the combined action of CDDP and 17-AAG cleaved poly (ADP-ribose) polymerase (PARP) and caspase-3, which demonstrated that the reduction in both cell growth and cell number was mediated by apoptosis. Time-course experiments showed that reduction in X-linked inhibitor of apoptosis protein (XIAP) and phosphorylated Akt were concomitant with apoptosis. The results of the present study demonstrate that 17-AAG synergizes with CDDP and induces apoptosis in CDDP-resistant ESCC cell lines, and also that modulation of the Akt/XIAP pathway may underlie this synergistic effect. Combination therapy with CDDP and an HSP90 inhibitor may represent a promising strategy to overcome CDDP resistance in ESCC.

Related Articles

Journal Cover

February 2014
Volume 31 Issue 2

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Ui, T., Morishima, K., Saito, S., Sakuma, Y., Fujii, H., Hosoya, Y. ... Yasuda, Y. (2014). The HSP90 inhibitor 17-N-allylamino-17-demethoxy geldanamycin (17-AAG) synergizes with cisplatin and induces apoptosis in cisplatin-resistant esophageal squamous cell carcinoma cell lines via the Akt/XIAP pathway. Oncology Reports, 31, 619-624. https://doi.org/10.3892/or.2013.2899
MLA
Ui, T., Morishima, K., Saito, S., Sakuma, Y., Fujii, H., Hosoya, Y., Ishikawa, S., Aburatani, H., Fukayama, M., Niki, T., Yasuda, Y."The HSP90 inhibitor 17-N-allylamino-17-demethoxy geldanamycin (17-AAG) synergizes with cisplatin and induces apoptosis in cisplatin-resistant esophageal squamous cell carcinoma cell lines via the Akt/XIAP pathway". Oncology Reports 31.2 (2014): 619-624.
Chicago
Ui, T., Morishima, K., Saito, S., Sakuma, Y., Fujii, H., Hosoya, Y., Ishikawa, S., Aburatani, H., Fukayama, M., Niki, T., Yasuda, Y."The HSP90 inhibitor 17-N-allylamino-17-demethoxy geldanamycin (17-AAG) synergizes with cisplatin and induces apoptosis in cisplatin-resistant esophageal squamous cell carcinoma cell lines via the Akt/XIAP pathway". Oncology Reports 31, no. 2 (2014): 619-624. https://doi.org/10.3892/or.2013.2899